What is MedAware?
MedAware operates at the intersection of artificial intelligence and clinical risk management, providing a sophisticated platform designed to identify and prevent medication-related errors. By integrating directly with existing electronic health records and hospital information systems, the company offers a critical safety layer that monitors patient data in real-time. This technological intervention is essential for modern healthcare providers, as it enhances decision support and operational efficiency. MedAware's market position is defined by its ability to transform raw clinical data into actionable insights, thereby reducing the incidence of preventable adverse drug events in diverse care settings.
How much funding has MedAware raised?
MedAware has raised a total of $9.3M across 3 funding rounds:
Grant
$25K
Other Financing Round
$1.3M
Series A
$8M
Grant (2015): $25K with participation from MedTech Innovator companies
Other Financing Round (2016): $1.3M led by Winton Ventures and OurCrowd
Series A (2017): $8M supported by OurCrowd, Gefen Capital, and Becton, Dickinson and Company
Key Investors in MedAware
Becton, Dickinson and Company
BD is a global medical technology leader that develops and manufactures medical devices, diagnostic systems, and healthcare solutions, focusing on patient safety and drug delivery innovation.
Gefen Capital
Gefen Capital is a venture capital firm that employs a flexible investment strategy, focusing on US-facing companies with strong technological differentiation and significant market potential.
OurCrowd
OurCrowd is a prominent investment platform based in Israel that facilitates capital allocation from accredited investors and institutions into high-growth startups and venture funds.
What's next for MedAware?
With the support of major enterprise-level funding, MedAware is poised to accelerate its product roadmap and expand its footprint within the hospital and clinic sectors. The strategic focus will likely shift toward deepening the integration capabilities of its AI engine and expanding its diagnostic reach. As the company transitions from its earlier growth phases into a more mature enterprise-level entity, the emphasis will remain on scaling its safety monitoring solutions to meet the increasing demand for automated clinical oversight. Future initiatives will likely prioritize the enhancement of predictive analytics to further reduce medication errors, solidifying MedAware's status as a cornerstone of modern patient safety technology.
See full MedAware company page
